<DOC>
	<DOCNO>NCT00183963</DOCNO>
	<brief_summary>The subject trial diagnose pre-cancerous disease breast call ductal carcinoma situ ( DCIS ) . This condition associate development breast cancer 50 % case . The subject ask participate research study . They offer voluntary admission study test effect new investigational drug call Fulvestrant ( Faslodex ) . This drug approve United States Food Drug Administration ( FDA ) treatment advance breast cancer approve treatment DCIS . However , FDA give permission drug test study . The purpose study find Fulvestrant effect subject 's precancerous change compare sample take receive Fulvestrant .</brief_summary>
	<brief_title>A Pilot Clinical Trial Evaluate Biological Activity Fulvestrant Breast Ductal Carcinoma Situ ( DCIS )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman newly diagnose DCIS . Women consider menopause fall one follow group : Age &gt; 60 Age &gt; 45 amenorrhea &gt; 1 year intact uterus Status post bilateral oophorectomy FSH/estradiol level postmenopausal range institution DCIS must diagnose minimally invasive biopsy technique , vacuumassisted large core tool ( Mammotome ) equivalent method . There must available tissue diagnostic biopsy perform molecular marker . Baseline mammogram within 8 week study entry . Serum creatinine less equal 2.0 mg/dl . Total bilirubin less equal 2.0 upper limit normal ( ULN ) , transaminase ( SGOT and/or SGPT ) alkaline phosphatase may 2.5 x institutional upper limit normal ( ULN ) , AGC great equal 1500 , platelet great equal 100,000 , Hemoglobin great equal 8.0 g/dl Peripheral neuropathy grade 01 . No prior therapy DCIS . SWOG performance status less equal 1 All patient must provide informed write consent Prior hormonal therapy ( antiestrogens , estrogen , SERM 's , progestins , aromatase inhibitor ) within 6 month study entry . Underlying medical , psychiatric social condition would preclude patient receive treatment . History DVT Pulmonary Embolism</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>